Received: 20 December 2019
Accepted: 17 April 2020
First Online: 6 May 2020
: The present study was carried out in accordance with the European Communities Council Directive of September 22nd 2010 (2010/63/EEC) for care of laboratory animals and after approval of the local government committee for nature, environment and consumer protection (LANUV NRW, TVA 81-02.04.2017.A482).
: Not applicable.
: TG received travel reimbursement from Sanofi Genzyme and Biogen Idec, none related to this manuscript. JM received travel grants from Biogen idec, Novartis AG, Teva, and Eisai GmbH; his research is funded by Klaus Tschira Foundation and Ruhr-University, Bochum (FoRUM-program); none related to this work. BA received travel funding from Novartis, has been employed by Celgene GmbH, and received research support from FORUM Anschubfinanzierung, Medizinische, Faktultät Ruhr-Universität Bochum. GE received speakers or scientific grant support from Biogen Idec, TEVA Pharma, Bayer Healthcare, Roche, Almirall, and Novartis Pharma. RG serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis, none related to this manuscript. KP received travel funding and speaker honoraria from Biogen Idec, Novartis, and Bayer Schering Pharma and funding from the Ruhr-University, Bochum (FORUM-Program). MS, AB, HB, and RK have nothing to declare.